AKTX
- Akari Therapeutics, Plc
()
Overview
Company Summary
Akari Therapeutics, Plc is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments for various immune-inflammatory and orphan diseases. The company's primary area of expertise lies in complement-mediated diseases, which are conditions caused by dysregulation of the immune system's complement system.
Akari Therapeutics is particularly engaged in developing treatments that target the alternative pathway of the complement system for specific disorders. The alternative pathway is responsible for amplifying immune responses and inflammation, and its dysregulation can lead to various diseases.
The company's lead product candidate is Nomacopan (formerly known as Coversin), a small protein drug that specifically targets and inhibits complement component 5 (C5) and leukotriene B4 (LTB4), both of which play key roles in inflammatory processes. Nomacopan has shown potential in multiple conditions, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and thrombotic microangiopathy (TMA).
Additionally, Akari Therapeutics is exploring the use of Nomacopan in other indications, such as bullous pemphigoid, systemic lupus erythematosus, and pediatric hematopoietic stem cell transplant-related diseases.
The company is dedicated to conducting clinical trials to evaluate the safety and efficacy of their drug candidates, with the ultimate goal of obtaining regulatory approvals and bringing these treatments to market. Through their research and development efforts, Akari Therapeutics aims to provide novel and effective therapeutic options for patients suffering from complement-mediated diseases and related conditions.